Literature DB >> 2156037

Impaired chemotactic responses of bronchoalveolar leukocytes in experimental pneumoconiosis.

K Donaldson1, G M Brown, D M Brown, J Slight, M D Robertson, J M Davis.   

Abstract

Rats were exposed to clouds of the following pneumoconiotic dusts: quartz, coal-mine dust, and chrysotile asbestos at 10 or 50 mg/m3 for 8, 32, and 75 days; for comparison, rats were also exposed to the non-pathogenic dust titanium dioxide (TiO2). The bronchoalveolar leukocytes (macrophages and neutrophils) from dust-exposed and control rats were obtained by lavage and tested for their ability to migrate toward zymosan-activated serum. Varying amounts of neutrophils were present depending on the ability of the dust to cause inflammation and the length of exposure. There was a marked loss of chemotactic ability in leukocytes from rats inhaling the pneumoconiotic dusts compared with controls; TiO2-exposed leukocytes had some impairment of chemotaxis, but this was substantially less than that found with the pneumoconiotic dusts. The loss of chemotactic activity did not correlate with the percentage of neutrophils in the lavage cells except when there were very high levels of neutrophils, and there was substantial impairment of chemotaxis with negligible numbers of neutrophils, showing that macrophage chemotaxis was impaired. A phagocytic burden within the leucocytes was not sufficient alone to inhibit chemotaxis, nor was the loss of chemotactic activity due to occupied receptors, since incubation failed to restore chemotaxis. Loss to chemotactic activity by leukocytes from pneumoconiotic dust-exposed lung could be an important factor in the development of pneumoconiosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156037     DOI: 10.1002/path.1711600113

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Extracellular matrix components in bronchoalveolar lavage fluid in quartz exposed rats.

Authors:  A Eklund; G Tornling; E Blaschke; T Curstedt
Journal:  Br J Ind Med       Date:  1991-11

2.  Coalmining, emphysema, and compensation.

Authors:  A Seaton
Journal:  Br J Ind Med       Date:  1990-07

3.  Surfactant prevents quartz induced down-regulation of complement receptor 1 in human granulocytes.

Authors:  G Zetterberg; J Lundahl; T Curstedt; A Eklund
Journal:  Inflammation       Date:  1997-02       Impact factor: 4.092

Review 4.  New perspectives on basic mechanisms in lung disease. 5. Respirable industrial fibres: mechanisms of pathogenicity.

Authors:  K Donaldson; R C Brown; G M Brown
Journal:  Thorax       Date:  1993-04       Impact factor: 9.139

5.  Presence of serum modulates expression of complement receptor type 1 (CR1) on human granulocytes after quartz exposure.

Authors:  J Lundahl; A Eklund; J Hed; G Tornling; M Vitas
Journal:  Inflammation       Date:  1993-08       Impact factor: 4.092

6.  Increased inflammation and altered macrophage chemotactic responses caused by two ultrafine particle types.

Authors:  L C Renwick; D Brown; A Clouter; K Donaldson
Journal:  Occup Environ Med       Date:  2004-05       Impact factor: 4.402

7.  N-acetyl-beta-D-glucosaminidase activity within BAL from macaques exposed to generic coal dusts.

Authors:  P A Mack; J W Griffith; S Riling; C M Lang
Journal:  Lung       Date:  1995       Impact factor: 2.584

8.  Carbon black nanoparticles induce type II epithelial cells to release chemotaxins for alveolar macrophages.

Authors:  Peter G Barlow; Anna Clouter-Baker; Ken Donaldson; Janis Maccallum; Vicki Stone
Journal:  Part Fibre Toxicol       Date:  2005-12-06       Impact factor: 9.400

9.  Persistent inflammation and impaired chemotaxis of alveolar macrophages on cessation of dust exposure.

Authors:  G M Brown; D M Brown; K Donaldson
Journal:  Environ Health Perspect       Date:  1992-07       Impact factor: 9.031

Review 10.  Minerals, fibrosis, and the lung.

Authors:  A G Heppleston
Journal:  Environ Health Perspect       Date:  1991-08       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.